DCM
FULC icon

Driehaus Capital Management’s Fulcrum Therapeutics FULC Stock Holding History

Driehaus Capital Management’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-243,388
Closed -$2.75M – 391
2025
Q4 		$2.75M Buy
+243,388
New +$2.48M 0.02% 325
2021
Q2 		– Sell
-876,211
Closed -$10.3M – 470
2021
Q1 		$10.3M Buy
+876,211
New +$10.8M 0.15% 199

Other funds holding FULC

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
FTM
First Turn Management Del Mar, California $895M AUM 261.28% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Driehaus Capital Management's FULC Position: Q1 2026 in Review

Driehaus Capital Management sold out of Fulcrum Therapeutics (FULC) in Q1 2026, closing a stake of 243,388 shares — an estimated $2.75M sold.

Driehaus Capital Management first reported a position in FULC in Q1 2021 and held it in 2 quarters. The position peaked at $10.3M in Q1 2021. 169 funds tracked by Wall St. Rank hold FULC as of Q1 2026.

  • Driehaus Capital Management reported no remaining Fulcrum Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Driehaus Capital Management sold 243,388 Fulcrum Therapeutics shares in Q1 2026, an estimated $2.75M.
  • Driehaus Capital Management first reported a position in Fulcrum Therapeutics in Q1 2021 and held it in 2 quarters.
  • Driehaus Capital Management's Fulcrum Therapeutics position peaked at $10.3M in Q1 2021.
  • 169 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q1 2026.

Based on Driehaus Capital Management's 13F filing for Q1 2026, filed 15 May 2026.